Announcement to Shareholders Regarding the Annual General Meeting of Shareholders of the Company

We hereby annouce to the Shareholders of PT Kalbe Farma Tbk. (hereinafter referred to as the “Company”) that the Annual General Meeting of Shareholders of the Company (the “Meeting”) will be convened on Thursday, May 14th 2009.

In compliance with the provisions of Article 21 paragraph (2) of the Company’s Articles of Association, an invitation of the Meeting will be advertised in 2 (two) Indonesian daily newspapers, 1 (one) which has a nationwide circulation and 1 (one) which is circulated at the domicile of the Company on April 29th 2009.

Those who reserve the right to attend or be presented in the Meeting are:

1. The Company’s Shareholders whose names are registered in the Register of Shareholders of the Company on April 28th 2009 not later than 4.00 pm Western Indonesia Time,


2. For shares in the Collective Custody, only the account holders or their proxies whose names are registered in the account holders or custodian bank at PT Kustodian Sentral Efek Indonesia (“KSEI”) on April 28th 2009 not later than 4.00 pm Western Indonesia Time; and


3. Holders of KSEI’s securities account in the Collective Custody shall provide List of Shareholders they manage to KSEI to obtain a Written Confirmation For the Meeting (“KTUR”).
   Please be advised that proposals from Shareholders for inclusion in the agendas of the Meeting must be submitted pursuant to the provisions of Article 21 paragraph (6) of the Company’s Articles of Association and received by the Board of Directors at least 7 (seven) days before April 29th 2009.
   

Jakarta, April 14th 2009

The Board of Directors

BAHASA

TheraCIM drawn attention at Asian Oncology Summit

The inaugural Asian Oncology Summit (AOS) – 2009 was held at Suntec Singapore International Convention & Exhibition Centre, Singapore. AOS major success is to have a partnership with South East Asian Medical Oncology Forum (SEAMOF) to encourage collaboration among oncologists in Southeast Asia. The Summit encompassed a series of plenary lectures covering a variety of haematological and solid cancers. There were additional six parallel suites dedicated to haemato-oncology, head and neck, gastrointestinal, breast, lung, and gynaecological cancer. The summit described the latest clinical needs for oncologists in Asia and offered an opportunity for the exchange ideas and thoughts that will help inform clinical practice. Notable international experts includes Prof Harald zur Hausen (Nobel Laureate) had discussed topics of pertinent clinical relevance.

During AOS, experts in oncology shared their experience how to combat cancer incidences and treatment strategy in various cancer types. It was estimated that 58.8 million people died globally from cancer in 2004 (WHO 2008). In South East Asia, it is estimated that in 2008 there were 1,589,000 incident cases of cancer (758,000 in men and 831,000 in women) and 1,072,000 deaths from cancer (approx 557,000 in men and 515,000 in women). In men, the commonest cancer was lung cancer, followed by oral cancer and in women, cervix and breast cancer were the commonest incident.

A panel of speakers had delivered speech on currently available targeted therapy in combination of conventional treatment, and stratified drug therapy with respect to cancer genetics. Targeted therapy has been encouraging the oncologists in the treatment of haematological and solid tumors. Small molecules (tyrosine kinase inhibitors; TKIs) as well as biologics (monoclonal antibodies; mAb) have been evaluated in different tumors in combination with chemotherapy (CT) and/or radiotherapy (RT). TKIs (gefitinib, imatinib, sorafinib, sunitinib) and mAb (cetuximab, trastuzumab, bevacizumab, nimotuzumab) described therapeutic efficacy in binding to their respective targets and hence improved in response rate to the treatment. Some of the clinical trials with targeted therapy have shown an increase in progression-free survival (PFS) as well as overall survival (OS) rate in cancers such as breast, head and neck etc. However, some of the anti-EGFR agents have been associated with severe toxicity in cancer patients.

During the recent summit, nimotuzumab (TheraCIM) had drawn attention by the oncologists and scientists from different parts of the world for its “affinity-optimized^TM” properties towards EGF receptor. Dr Rikrik Ilyas, director, Innogene-Kalbiotech, Singapore had described the development and therapeutic efficacy of nimotuzumab in treating tumors with high EGFR expression. Nimotuzumab is a humanised monoclonal anti-EGFR antibody with reduced toxicity and immunogenicity, and has been approved for the treatment of nasopharyngeal carcinoma (NPC), SCCHN and glioma. The combination of nimotuzumab and RT has significantly increased overall response rate in patients with NPC and other advanced stage head and neck cancers.

During a satellite symposium organised at AOS by Innogene-Kalbiotech, Prof Mark Vincent from University of Western Ontario, Canada explained that “nimotuzumab efficacy in the treatment of EGFR over-expressed tumors is similar to other anti-EGFR agents, cetuximab and panitumumab. Regarding toxicity, nimotuzumab discriminates cells with respect to EGFR expression by binding preferentially to tumor cells over-expressing EGFR, whereas cetuximab and panitumumab bind to all tissues expressing EGFR. The attachment of nimotuzumab to EGFR required bivalent binding, which occurs more readily when EGFR density is elevated. In contrast, when EGFR density is low, such as in healthy tissue, cetuximab and panitumumab continued to interact strongly with EGFR through monovalent binding, while nimotuzumab monovalent binding was transient thus sparing healthy tissues and avoiding the associated severe toxicities. An “affinity-optimized^TM” property of nimotuzumab has shown superior safety profile while exhibiting similar therapeutic efficacy compared to other anti-EGFR mAbs. Severe hypomagnesemia and skin rash is common with the treatment of cetuximab and panitumamab. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer has been reported”.

A positive relation between the presence and severity of treatment-related rash and survival has been consistently observed with all ant-EGFR agents approved for clinical use. These findings suggest that rash may be a useful surrogate marker of successful EGFR inhibition and clinical benefit and therefore of possible use in identifying patients most likely to benefit from therapy, as well as to guide dose adjustments. However, absence of skin rash with the treatment of nimotuzumab makes it a unique therapeutic agent among the class of anti-EGFR mAb.

In a statement given by Prof Randolph HJ, UCLA “the rash is not only unsightly but is painful and can lead to serious infections. I have had patients require urgent surgical drainage of abscesses related to EGFR rashes. EGFR inhibitor with anticancer activity, but without skin toxicity, would be a great advance for patients”

Nimotuzumab has therefore emerged as a promising therapeutic option for patients with advanced epithelial tumours.

The second Asian Oncology Summit being planned to host at Bali, Indonesia (April 9-11, 2010).

PT Kalbe Farma Tbk, grows 12,5% in 2008

Based on Audited Consolidated Financial Statements for the Year Ended on December 31, 2008, PT Kalbe Farma Tbk. and subsidiaries (“The Company”) has achieved net sales of Rp 7.9 Trillion, 12.5% higher compared to Rp 7.0 Trillion in 2007.

The Company’s gross profit reached Rp 3.8 Trillion in 2008, an increase of 7.1% compared to the previous year figure. Due to increase of raw material prices and depreciation of Rupiah against USD, the Company’s gross profit margin has declined to 48.3% from the the previous year figure of 50.7%.

The Company’s operating expenses in 2008 was Rp 2.7 Trillion, or 9.9% higher than the previous year. The largest component of operating expenses was selling expenses of Rp 2.1 Trillion, followed by general and administration expenses of Rp 453 Billion and research and development expenses of Rp 54 Billion. Operating expenses ratio to net sales decreased 0.8% to 33.8% in 2008 compared to 34.6% in 2007.

In 2008, the Company was able to maintain its net income amounting to Rp 707 Billion, an increase of 0.2% compared to Rp 706 Billion in 2007.

The details of each Division performance are as follows:

* Prescription Pharmaceuticals Division, as the main business division of the Company, contributed 27.1% of the total net sales. In 2008, the division reported net sales of Rp 2,131 Billion, 18.0% higher than the previous year.
* Consumer Health Division net sales contributed 20,9% of the total net sales. The division reported net sales of Rp 1,648 Billion. As sales of Energy Drink has not yet recovered in 2008, this division net sales has been down by 11.2% compared to that of previous year.
* Nutritionals Division, the Company’s fastest growing division, contributed 24.5% of the total net sales. This division has successfully achieved its net sales of Rp 1,927 Billion or grew 20.5% compared to Rp 1,600 Billion in 2007.
* Distribution and Packaging Division also made significant contribution to total net sales at 27.5%. This division successfully reported net sales of Rp 2,170 Billion with the highest sales growth of 24.5% in 2008 compared to the previous year.

At the end of 2008, the Company increased its net income per share to Rp 72, grew 2.9% compared to Rp 70 in 2007.

This information will be available on the Company’s website at www.kalbe.co.id or for further information please contact:

Vidjongtius / Corporate Secretary
PT Kalbe Farma Tbk.
Gedung KALBE
Jl. Let. Jend. Suprapto Kav. 4
Cempaka Putih – Jakarta
Phone: (021) 428-73688
Fax : (021) 428-73678
Email : vidjongtius@kalbe.co.id


BAHASA

RISTEK - Kalbe Science Awards 2008 : The Finalists

Indonesia is one nation that is abundant in its nature wealth. Many flora and fauna have been traditionally used for health care to treat various health disorder / disease in the its population. Unfortunately, although there have been already so many research done, there are still lack of effort in coordinating the research activities to make the potential become reality.
Kalbe.co.id - Meanwhile, research on medicinal plants from Indonesian origin and other advanced & applicable medical research for Indonesian people are mostly done by scientists from outside Indonesia. On the other side, there are so many potential Indonesian scientists having plenty of intellectual resources, including in medical research field. However, many of the Indonesian scientists often carried out the research that was for academic purpose only. Once they have obtained a degree, the research results are stored neatly in a table or cabinet.

To overcome the gap between the scientists and the industries (in this case, the pharmaceutical industry), the State Ministry of Research and Technolgy Republic of Indonesia (RISTEK) co-operates with the biggest pharmaceutical company in South-East Asian, Kalbe Farma, held the award for the scientists . It's called Ristek-Kalbe Science Awards 2008.

This competition is looking for results of the medical related research in the field of:

• pharmaceutical raw materials obtained by applying phytochemistry, biotechnolgy, and medicinal chemistry
• pharmaceutical dosage forms by applying pharmaceutical technology
• medical diagnostics
• health food

There are two (2) categories for these awards:

1. Young Scientist Awards, seeking for one (1) awardee (winner) with IDR 50,000,000 prize
2. Best Research Awards, seeking for three (3) awardees with IDR 50,000,000, 30,000,000 and 15,000,000 prizes

The interest of researcher was high, reflected by hundreds of papers that have been submitted.

Below is the finalist from the 2 categories (in alphabetical order) :


10 Best Research finalists :

• Akhmad Kharis Nugroho, M.Si., Apt - Bagian Farmasetika Fakultas Farmasi UGM
• Agus Zainal Arifin, S.Kom., M.Kom - Institut Teknologi Sepuluh November, Surabaya
• Arief Budi Witarto - Puslit Bioteknologi LIPI Cibinong
• Heni Rachmawati, Apt., M.Si - Sekolah Farmasi ITB
• Khie Khiong, S.Si., M.Si., M.Pharm. Sc., Ph.D - Divisi Imunologi Puslit Ilmu Kedokteran (PPIK), FK Maranatha
• Maggy Thenawidjaja Suhartono, Prof. - Institut Pertanian Bogor
• Maria Immaculata Iwo, M.Si., Apt. - Sekolah Farmasi ITB
• Ronny Martien, Dr.rer.nat., M.Si - Fakultas Farmasi, Universitas Gadjah Mada
• Sukmadjaja Asyarie, Dr. - Sekolah Farmasi ITB
• Sunu Budhi Rahardjo, dr. Ph. D - Divisi Litbang PJN Harapan Kita

5 Young Scientist finalists :

• Akhmad Kharis Nugroho Dr., M.Si Apt. - Fakultas Farmasi UGM
• Heni Rachmawati, Dr. Apt., M.Si - Sekolah Farmasi ITB
• I. Sahidin, Dr. M.Si - Jurusan Kimia, Fakultas MIPA Universitas Haluoleo
• Supangat dr. M. Kes Ph.D - Fakultas Kedokteran Universitas Jember
• Tri Agus Siswoyo, M. Agr., Ph.D - Fakultas Pertanian Universitas Jember

BAHASA

Announcement Of Resolution Of Extraordinary General Meeting Of Shareholders PT KALBE FARMA Tbk. (“Company”)

It is hereby announced to all shareholders of PT Kalbe Farma Tbk. (hereafter referred to as “the Company”), that the Company’s Extraordinary General Meeting of Shareholders (EGMS) held on Wednesday, 17 September 2008 was declared to be legally authorized to make decision as the EGMS was attended by shareholders representing at least 2/3 (two thirds) of the total shares with lawful voting rights and approved by at least 2/3 (two third) of the total votes lawfully cast at the meeting.

EGMS has adapted resolutions which are mainly as follows:

1. Resolved to approve that the Company shall execute Shares Buy Back Phase II on the terms and conditions as follows.


a.the Shares Buy Back Phase II shall be implemented by the Company after the date of EGMS and shall be executed from time to time in 18 (eighteen) months starting from the date from the date of EGMS;


b.the total number of shares to be repurchased shall not exceed 5,1 % of the total number of shares issued by the Company up to the date of EGMS, or a maximum of 518.339.442 shares of the total number of shares issued and fully paid by the Company, or a total of 10.156.014.422 shares;


c.the funds for executing repurchasing shares (inclusive of transaction costs, broker fees, and other expenses related to the Shares Buy Back Phase II) shall be charged against the Company’s unappropriated retained earnings, provided that the fund shall not exceed Rp. 419.855.000.000,00 including all expenses in connection with preparation of the Company’s Shares Buy Back Program; and


d.the Shares Buy Back Phase II shall be executed on the terms and conditions and according to the procedures publised in :

i.“Information to Shareholders in Relation to the Proposed Plan To Conduct a Second Buy Back of Shares of PT Kalbe Farma Tbk.” announced in advertisements in daily newspapers Bisnis Indonesia and Investor Daily Indonesia, all dated 15 August 2008 and 15 September 2008 as previously disclosed above; also

ii. The provisions of the prevailing statutory regulations. Repurchased shares shall be treated as the treasury stocks and might be sold if the price has increased in such a manner that upon the Company’s consideration it shall bring gain to the Company and shall not be resold to the Company’s employees under ESOP and/or MSOP program.


e.to ratify and approve the appointment of institution and supporting professionals which have been appointed by the Company in connection with the Shares Buy Back Phase II, including the appointment of PT. Danareksa Sekuritas to act as the Security Trading Broker in the execution of shares repurchasing in the stock market.



2. Resolved to grant authority to the Company’s Board of Director to take all and any actions whatsoever required by of the prevailing statutory regulations, including but not limited to:
i.determine the purchase price of shares buy back; and
ii.determine the selling price of the repurchased shares.

BAHASA

PT. Kalbe Farma Tbk. Announced 2007 Full Year Audited Results

JAKARTA, Indonesia – March 31, 2008 – PT Kalbe Farma Tbk. (“Kalbe”) released full year 2007 audited report.
Kalbe has recorded revenue of IDR 7.00 trillion or an increase of 15.3% compared to the revenue of IDR 6.07 trillion in 2006. Kalbe’s growth in 2007 had exceeded the growth of national pharmaceutical industry.

The details of each Division’s performance are as follows:

• Consumer Health DivisionThis Division consists of 3 sub-divisions i.e. Nutritional, Over-the-Counter and Energy Drink. In 2007, this Division recorded revenue of IDR 3.46 trillion or increase of 9.3% compared to IDR 3.16 trillion recorded in 2006, with the largest contribution and highest growth from Nutritional.
• Prescription Pharmaceutical DivisionThis Division contributed 25.8% to the total consolidated sales in 2007 and recorded revenue of IDR 1.81 trillion or 24.0% higher than IDR 1.46 trillion in 2006. Kalbe had successfully integrated its Marketing Department in 2006 and the benefit had been realized in 2007.
• Distribution and Packaging DivisionThis Division contributed 24.9% to total consolidated revenue and recorded third parties’ revenue of IDR 1.74 trillion in 2007, 20.0% higher than recorded revenue of IDR 1.45 trillion in 2006. This good growth was due to the new principals acquired.

Kalbe recorded gross profit of IDR 3.55 trillion or 14.6% higher compared to IDR 3.10 trillion in 2006. Gross profit margin decreased from 51.0% of Net Sales last year to 50.7% of Net Sales this year. This is due to the price increase of raw materials and changes of Kalbe’s business portfolio.

Operating expenses in 2007 was IDR 2.42 trillion or increased by 19.5% compared to IDR 2.03 trillion in 2006. The increase in operating expenses was due to increase in marketing activities to maintain and increase market share of Kalbe’s product, increase in transportation and delivery costs in Distribution Division and increase in research and development expenses. Kalbe has always made efforts to optimize its expenses in line with its sales growth.

Operating Profit reached IDR 1.13 trillion which was 5.4% higher than IDR 1.07 trillion recorded in 2006. Operating profit ratio decreased from 17.6% of Net Sales in 2006 to become 16.1% of Net Sales this year.

The Company posted net profit of IDR 706 billion or 4.3% higher than IDR 677 billion recorded in 2006.

With regards to the share buy-back programs, up to March 27, 2008, Kalbe has bought back 327.975.500 shares with total transaction of IDR 386.090.222.969.

This information will be available on Kalbe’s website at www.kalbe.co.id or for further information please contact:
Vidjongtius / Corporate Secretary
PT Kalbe Farma Tbk.
KALBE Building
Let. Jend. Suprapto Kav. 4
Cempaka Putih – Jakarta
Indonesia Phone : (6221) 428-73688
Faximile: (6221) 428-73678
Email : vidjongtius@kalbe.co.id

Kalbe Collaborates With IBM to Build Green Data Center and Reduce Energy Consumption

IBM (NYSE: IBM) and Kalbe today announced a collaborative effort to build a new energy efficient "green data center" and undergo a major data center consolidation project, in order to meet Kalbe's technology requirements of its expanding business, while simultaneously saving energy.

A leading pharmaceutical and health company in Indonesia, Kalbe is teaming with IBM to deploy data center consolidation with an explicit goal of reducing energy consumption as well as reducing information technology (IT) maintenance and space in its own data center facilities across Jakarta. IBM will help Kalbe to consolidate five data centers from its current 13 existing data centers during the initial phase.

In addition, IBM will install a green data center on a site of 5,048 square feet. Other site and facilities services and server services to be implemented include data center strategy, data center design, server and storage integration, relocation planning, project management, infrastructure equipment sourcing, installation services and management, data center testing and startup management."

Kalbe is expanding its business into the pharmaceuticals and consumer products segments by developing various products and providing a technology-based electronic distribution system," said Mr. Vidjongtius, information technology director, Kalbe. "In addition to supporting our fast expanding business, we believe the time is right for Kalbe to make a cost- saving and energy-saving purchase. The IBM data center solution allows us to concentrate on continuing to provide the production system and staff with the tools necessary to succeed, while also being environmentally conscious."

"IBM's long history and expertise with data center implementations enabled us to create a solution to save energy and ensure efficient server performance for Kalbe," said Hengkie Kastono, Country Manager, Global Technology Services, IBM Indonesia. "IT departments won't be as concerned with growing energy costs when selecting IBM's data center solutions, which provide an efficient, reliable and secure data center. IBM is making it easier for data center owners to go green with new, more energy efficient technology and services, available as part of IBM's Project Big Green initiative."

IBM has the deep experience to implement the entire solution in eight to 24 weeks, compared to the industry norm which is about 40 weeks. The IBM data center solution integrates power, cooling, rack, management, services and security, allowing for selection of standardized components to create a solution through modular configurations. By using standardized components, the architecture easily scales to meet the evolving needs of the company.

This agreement was signed in the fourth quarter of 2007.

About IBM

Project Big GreenAnnounced in May 2007, Project Big Green is a $1 billion initiative to dramatically reduce energy use by IBM and its clients. The initiative includes new energy efficient IBM products and services and a five step approach to energy efficiency in the data center. If followed, this approach can sharply reduce data center energy consumption, transforming clients' technology infrastructure into "green" data centers and provide energy savings of up to 42 percent for an average data center. The initiative also includes a new global "green team" of more than 850 energy efficiency architects from across IBM. More information about IBM Project Big Green is available at www.ibm.com/press/projectbiggreen.

About Kalbe

PT Kalbe Farma Tbk. ("Kalbe") is one of the leading pharmaceuticals and health products companies in Indonesia and is recognized as the largest regional pharmaceutical company in Southeast Asia. Established in 1966, Kalbe's aim is to assist Indonesians to achieve a higher quality of life by providing them with products that improve their health and well-being. The company's main areas of business activities are the production, distribution, marketing and packaging of pharmaceuticals, health foods and other consumer products. For more information on Kalbe, please visit www.kalbe.co.id/?lang=English.

(source: CNN Money)

PT. Kalbe Farma Tbk. Received ASEAN Business Award

PT Kalbe Farma Tbk. (“KLBF”) today announced receipt of ASEAN Business Award.

Kalbe received the ASEAN Business Award as the winner for the Corporate Social Responsibility category in the ASEAN Business and Investment Summit 2007 held in Singapore on November 18, 2007.

Kalbe was the only company from Indonesia who received the award and had been honored as one of the most admired ASEAN Enterprises.

The ASEAN Business Award was held for the first time by ASEAN Business Advisory Council, a council established by the head of ASEAN countries on the 7th ASEAN Summit at Bandar Seri Begawan, Brunei Darussalam on November 2001.

The qualifying criteria among others are ASEAN-incorporated enterprises with at least 40% ASEAN equity, ASEAN presence (operating in two or more ASEAN countries), Annual revenue of at least USD 20 million, and potential to become a global company in the future.

Further, all participants were selected and assessed based on 4 categories: Growth, Innovation, Employment and Corporate Social Responsibility.

“This award is the recognition for Kalbe as one of the best companies in ASEAN, not only in Indonesia. In the future, Kalbe will continuously improve its capability in all areas, not only in corporate social responsibility activities, but also in innovation, employment and growth,” said Johannes Setijono, CEO of Kalbe.

BAHASA

Kalbe's corporate bond ratings is upgraded to AA

Kalbe.co.id - One of Indonesia's most reputable rating agency: PT Pemeringkat efek Indonesia (Pefindo) has just upgraded Kalbe and its 2006's IDR 300 billion corporate bond to become id AA from id AA- for the period Jun 29, 2007 until Jun 1, 2008. This rating outlook is in the "stable" category.

BAHASA

PT. Kalbe Farma Tbk. Annual General Meeting of Shareholders

In the year 2006, PT Kalbe Farma Tbk. (“the Company”) recorded net sales of IDR 6.07 trillion, 3.42% higher if compared to 2005’s figures of IDR 5.87 trillion. The year of 2006 is often referred to as “The Restructuring Year” by the Management because they have undertaken many projects in order to produce synergies. These synergies are one of the objectives why the Company did a merger the year before.

The Company’s gross profit in 2006 was IDR 3.1 trillion, or 4.57% higher if compared to the 2006’s figures. Some improvement can be seen in the gross profit margin; it has increased from 50.47% in 2005 to become 51.04% in 2006. This is mainly because of the strengthening and stabilizing of Indonesian Rupiah against the United States Dollar which caused reduction of the Company’s cost of imports of raw material.

Operating profit has also increased by 1.06% to become IDR 1.07 trillion if compared with 2005’s restated figures of IDR 1.06 trillion. Operating profit margin was reduced from 18.06% to become 17.64%. Low sales growth is mainly to blame for this.

The Company recorder 2006 net profit of IDR 677 billion, or 8.06% higher if compared to 2005’s restated figure of IDR 626 billion. This growth is mainly contributed by lower interest and financial expense as well as realized gain from foreign exchange.

The Company’s Annual General Meeting of shareholders held on May 22, 2007 has approved the following matters:

1. To approve director’s annual accountability for the year ended on December 31, 2006 as well as to approve and ratify the company’s planning for year 2007;

2. To approve and ratify the company’s yearly result for the year ended on December 31, 2006 which was audited by Public Accountant: Prasetio, Sarwoko & Sandjaja with its undoubted opinion, and to give full discharge of responsibility to the Board of Directors for their management and to the company’s Board of Commissioners for their supervision during the year ended on December 31, 2006 (acquit et de charge) as long as the results are reflected in the financial figures of Company’s annual report for the year ended on December 31, 2006;

3. a. To approve the allocation of the Company’s net profit for the year ended on December 31, 2006 to be as follows:

i. Acknowledging the Company’s execution of share buyback, each share will receive IDR 10 (ten rupiah), or up to IDR 101,560,144,220 (one hundred one billion five hundred sixty million one hundred forty-four thousand and two hundred twenty rupiah), will be given to shareholders as cash dividends;

ii. IDR 6,765,816,539 (six billion seven hundred sixty five million eight hundred sixteen thousand five hundred thirty nine rupiah) will be kept as an additional working capital for the Company;

iii. The remaining amount, IDR 568,255,693,113 (five hundred sixty eight billion two hundred fifty five million six hundred ninety three thousand one hundred thirteen rupiah) will be added to retained earnings;

b. To give authority to the Management to do everything that is needed in relation to the decisions stated in point (3a) above. All these decisions is in accordance to the prevailing rules and regulations which includes the preparation of carrying out the cash dividend payout.

4. a. To accept resignation request of Yosef Darmawan Angkasa as the Company’s Director and Rustiyan Oen as the Company’s Commissioner with appreciation of gratitude for their recorded supervision and services rendered; and to fully free them of their obligations and responsibilities. (acquit et de charge)

b. To approve the appointed Ferdinand Aryanto as the Company’s Commissioner as of the end of this AGM until the next AGM in 2008. This resulted in the following Management list:

President Director : Johannes Setijono

Vice President Director : Johanes Berchman Apik Ibrahim

Vice President Director : Budi Dharma Wreksoatmodjo

Director : Bernadette Ruth Irawati Setiady

Director : Santoso Oen

Director : Vidjongtius

Director : Herman Widjaja

Director : Justian Sumardi

President Commissioner : Boenjamin Setiawan

Commissioner : Nina Gunawan

Commissioner : Ferdinand Aryanto

Independent Commissioner : Johannes Baptista Soemarlin

Independent Commissioner : Inne Erna Adriana Soekaryo

d. To give full authority to the Company’s Board of Directors to notarized the new Board of Directors and Board of Commissioners lists and to report them to the appropriate government organization by way of registering it into the Company’s registered form or any necessary action needed to be done in accordance to the prevailing rules and regulations.

d. To give full authority to the meetings of the company’s Board of Commissioners to determine salary and incentive for member of Board of Commissioners and to give full authority to Board of Commissioners of the company to determine honorarium/salary for member of the company’s directors for year 2007;

5. To give full authority to Board of Commissioners and/or Directors of the company to appoint Public Accountant listed in Capital Market Supervisory Body for auditing the company’s bookkeeping for year 2007, also to give authority to the company’s board of directors to determine their honorarium and other appointment requirements.

BAHASA

Kalbe Farma Announced 2007 First Quarter Results

JAKARTA, Indonesia – Apr 30, 2007 – PT Kalbe Farma Tbk. (“Kalbe”) today released financial results for the year ended Mar 31, 2007.

“The main growth driver in this first quarter of 2007, is the Prescription Division. This division’s growth rate of more than 37% is much higher than its CAGR for the last five years. This is a clear evidence to indicate that more than ever before, we are more focused on building and maintaining our leading position in Indonesia’s pharmaceutical industry,” said Justian Sumardi, Corporate Secretary of Kalbe.

Mar 31, 2007 Financial Highlights

Revenues - Kalbe reported revenue of IDR 1.56 trillion for the first quarter of 2007, an increase of 8.65% compared to the previous year’s figure of IDR 1.43 trillion.

Prescription Revenues - Kalbe main business line, the Prescription Pharmaceutical Division, contributes 28.2% to the total consolidated revenues. This division reported revenue of IDR 437.94 billion, or 37.57% higher than the previous year’s performance. The main reason for this growth is that Kalbe has successfully completed one of its merger integration projects which is to reorganize the marketing divisions within the whole group. The reorganization has resulted in an increase of customer coverage by about 20%, and has also created new teams to cover several new therapeutic classes which were not covered before.

Nutritional Revenues - Kalbe’s 2^nd most important division is the Nutritional Division which contributes 23.2%. This division record revenues of IDR 360.23 billion, or 17.44% higher than the previous year’s figures. We believed that it could performed better just like before because Kalbe’s nutritional products are generally higher priced than the competitors’ to target the high income segment who is not significantly affected by the relatively recent fuel price hike. Although demand of Kalbe’s nutritional products has been consistently increasing considerably but this period’s growth is less than the division’s CAGR within the last four years. The main reason for this is that this division has been experiencing finished goods supply shortage problems. This problem is caused by one of the toll out manufacturing facilities. Fortunately, this condition will not persist for longer time because Kalbe’s new subsidiary, Kalbe Morinage Indonesia has just been inaugurated. The new factory has started its commercial production as of April 9, 2007.

Distribution Revenues - Kalbe’s Distribution Division contributes 20.7% of total consolidated revenues, it recorded revenues of IDR 321.2 billion, or 26.26% higher versus the previous year’s figures. Since this Division’s revenues figures only take account revenues generated from third parties’ products, the Management acquired more third parties to distribute through the division’s network.

OTC Revenues - Kalbe’s OTC Division performed quite poorly in this period if compared to the previous year. This division currently contributes 14.1% to the total consolidated revenues; it recorded revenues of IDR 218.79 billion, or 2.71% lower than the previous year’s figures. The Management believed that the reason for this poor performance is that the purchasing power of lower to middle income segment has not recovered strongly.

Energy Drink Revenues – Similar to the previous division, Kalbe’s Energy Drink Division is very much affected by the reduced consumer purchasing power effect. The main consumers for this divisions’ products are people who belong to the low income segment. The division currently contributes 10.5% to the total consolidated revenues. It recorded revenues of IDR 163.88 billion, or 37.8% lower than the previous year’s figures. One of the ways that Management has done is to launch 3 new flavors of Extra Joss: Grape, Cream Soda, and Apple in March 2007.

Packaging Revenues - Kalbe’s Packaging Division contribute 3.4% of the total consolidated revenues. It recorded revenues of IDR 53.34 billion, or 16.33% lower than the previous year. This Division’s revenues figures only take account revenues generated from providing packaging service to third parties’. The Management believed that the reason for this poor performance is that their costs has significantly increased due to the increasing fuel price. Furthermore, the whole industry itself is experiencing a slowdown mainly due to the slower economic consumption.

Gross profit - Gross profit is recorded at IDR 795.32 billion, 10.11% higher than the previous year’s. In parallel, gross profit margin increased from 50.5% of Net Revenues last year to become 51.1% of Net Revenues this year. This is due to the favorable and stable US Dollar exchange rate resulting in favorable cost of raw material that is mostly imported.

Operating Profit - Operating Profit reached IDR 331.82 billion, 5.01% higher than the previous year’s restated figures of IDR 315.99 billion.

Net Profit - However, the Company posted net profit of IDR 222.89 billion; 11.3% higher than 2006’s restated figure of IDR 200.26 billion. The growth is mainly contributed by the decrease of interest expense and realized gain/loss of foreign currency exchange.

KALBE FARMA Announced 2006 Full Year Audited Results

PT Kalbe Farma Tbk. (“Kalbe”) today released financial results for the year ended December 31, 2006.

“Although we only managed to record a single digit sales growth this year, we are quite pleased with the performance because once again we had successfully beat the pharmaceutical industry growth,” said Johannes Setijono, CEO of Kalbe. “The year 2006 was an unusual year for the pharmaceutical industry in Indonesia. The industry usually performed a double digit growth every year but according to IMS, an independent research company which specialized in pharmaceutical information analysis, the market size of the industry (OTC + Prescription drugs) for 2006 has a year-on-year growth rate of -1.9. This figure can be further segregated into -5.7% growth for the Prescription drugs and 4% growth for the OTC drugs.”

This abnormality is mainly due to two macro-level incidents that happened during the year. The first incident is that the Government has decided to greatly reduce the amount of fuel subsidies it is giving to the Indonesians. This happened approximately in the month of October of 2005. As a result fuel price increased by an average 100%. This resulted in a significantly hampered consumer purchasing power especially to the people that belong in the middle to lower earnings segment that experienced the hardest hit.

But an even more disrupting effect came from the new Government regulation which was announced effective as of July 2006. Due to pressure coming from the Government, the association of local pharmaceutical producers decided to take a preemptive action to voluntarily lower the prices of 34 active pharmaceutical ingredients which defines to approximately 1,400 prescription product SKUs in the national market. The price decrease ranges from 10% to 70% of the original price. The deadline given for every pharmaceutical producers to reduce their prices was October 2006. Another regulation that was passed in the same year was the price reduction of certain unbranded generic drugs up to 50%.

YE Dec 31, 2006 Financial Highlights

Revenues - Kalbe reported revenue of IDR 6.07 trillion for the year ended in December 31, 2006, an increase of 3.42% compared to the previous year’s figure of IDR 5.87 trillion. Given the “not so good performance” year, the year 2006 was a meaningful year to Kalbe because this is commonly called ”The Restructuring Year” as the BOD has overtaken several projects that are aimed to successfully integrate the previous 2005 merger.

Prescription Revenues - Kalbe main business line, the Prescription Pharmaceutical Division, contribute 24% to the total consolidated sales. This division reported revenue of IDR 1.46 trillion, or 8% higher than the previous year’s performance. The main reason for this growth is that Kalbe has successfully completed its integration project to reorganize the marketing divisions within the whole group, coupled with the fact that Kalbe is not as deeply affected by the price reduction regulation. Therefore this rarely happening single digit growth from the division is well received by the Management because it is considered to be a rewarding experience if we compare ourselves to the rest of the companies in the Prescription Industry that performed an average of -5.7% year on year growth. This fact further supports how Kalbe became the number 1 player in the prescription industry with a market share of 10.6% as stated by IMS by the end of 2006. In the same statistics report, Kalbe ranked 3^rd at the end of the previous year with a 9.4% market share.

Nutritional Revenues - Kalbe’s 2^nd most important division is Nutritional Division which contribute 21.8%. The division is also not spared by the macro-level incidents but still manage to record sales of IDR 1.32 trillion, or 21.4% higher than the previous year’s figures. We believed that one of the reasons for this somewhat high growth is that Kalbe’s Nutritional Division mainly manufactures a generally higher priced products which are targeted towards the high income segment people which is not as greatly affected by the fuel price hike.

OTC Revenues - Kalbe’s OTC Division performed quite poorly this year if compared to the previous years. This division contribute 15.5% to the total consolidated sales; it recorded sales of IDR 1.32 trillion, or 3.8% lower than the previous year’s figures. Although the OTC is not as regulated as the Prescription industry, the Management believed that the reason for this is the macro-level incidents that was mentioned earlier in this document as well as a significant reduction of OTC products exports to Nigeria.

Energy Drink Revenues - Kalbe’s Energy Drink Division is very much affected by the reduced consumer purchasing power effect. This Division is currently contributing 14.8% to the total consolidated sales. It recorded sales of IDR 896 billion, or 8% lower versus 2005 figures. We believed that one of the main reasons for this minus growth is that Indonesia’s Energy Drink Industry performed poorly. The energy drink industry is also facing a fierce competition from non head to head competitors in other beverage category such as vitamin water. On the other hand, the exports of our energy drink products is doing relatively well, such as our exports to Philippines.

Distribution Revenues - Kalbe’s Distribution Division contribute 19.9% of total consolidated sales, it recorded sales of IDR 1.21 trillion, or 3.1% lower versus the previous year’s figures. This Division’s sales figures only take account sales generated from third parties’ products. The Management believed that the reason for this minus growth is that the previous year’s performance which is used as a benchmark with 2006, still include the sales of products from two principals that parted their ways with us in 2005.

Packaging Revenues - Kalbe’s Packaging Division contribute 4% of the total consolidated sales. It recorded sales of IDR 246 billion, or 5.8% higher than the previous year. This Division’s sales figures only take account sales generated from providing packaging service to third parties’. The Management believed that the reason for this slow growth is that while the fuel price hikes significantly increased their costs. The industry itself is experiencing a slowdown mainly due to the slower economic consumption for the year.

Gross profit - Gross profit is recorded at IDR 3.1 trillion which is 4.57% higher than the previous year’s. At the same time gross profit margin increased from 50.47% of Net Sales last year to become 51.04% of Net Sales this year. This is due to the favorable and stable US Dollar exchange rate resulting in favorable cost of raw material that is mostly imported.

Operating expense - Operating expense increased by 6.52% versus the same period last year. The Company will further make utmost efforts to minimize its expenses particularly its selling expenses so as to be in proportion with its sales growth towards the year end.

Operating Profit - Operating Profit reached IDR 1.07 trillion which is 1.06% higher than the previous year’s restated figures which was IDR 1.06 trillion. Operating profit ratio decreased from 18.06% of Net Sales to become 17.64% of Net Sales this year.

Net Profit - However, the Company posted net profit of IDR 677 billion; or 8.06% higher than 2005’s restated figure of IDR 626 billion. The growth is mainly contributed by the decrease of interest expense and realized gain/loss of foreign currency exchange.

BAHASA

Kalbe Farma’s New Look, 6 March 2007

If you have accessed Kalbe’s website (http://www.kalbe.co.id) since 6 March 2007, you must have seen a different look compared to the days before. Starting with the logo, the web’s appearance also underwent a modification. This time Kalbe’s web looks more minimalist, informative and full with useful features. All these followed Kalbe’s new tag line, which is Life Enriching Science.


Front Page

The front page, which is usually called HOME is different with the previous one. The new look offers many conveniences. All the things that are frequently accessed by visitors are placed at the front page, namely: Annual report, Calendar of Event, Kalbe Offices (branch offices), Careers at Kalbe and Community are a group of articles under Kalbe’s web. All are Kalbe’s web characteristics that have been around all these time. Your first pit stop – to care for your health – and explore the Internet.


Additional Features: Health Consultation and My Kalbe

Several features were added or have their functions optimized, namely Health Consultation, which is a forum for health consultation. Users who want to ask will be asked to log in first.


Still Confused?

The web administrators urge the users to login every time they make a visit. Because when they are logged in (free sign up), users can personalized the web appearance. Any articles that are read frequently, can be placed at the front page and therefore it will look as minimalist as the user’s wished. Also, users can use other features as optimum as possible.

(Note: for Kalbe employees who already have a web-mail, there is no need to sign up. Please log-in using the given username and password).


Making a Better Life

All of these can make you feel more comfortable when you are browsing because we really care. With our new look that represents our care and attention for you, we are ready to give the best for all of you. We hold on to our commitment to keep dedicating science to enrich life.
With our new look, we are ready to step further into becoming a web with international standard in order to create a healthy and prosperous community.

Kalbe Shares: Post Flooding Social Service February 2007

No less than 10 doctors with 40 nurses and volunteers from Kalbe Shares came to TNI AL Kodamar Complex, North Jakarta, Thursday, 15 February 2007. PT Kalbe Farma Tbk did this post-flooding social service in collaboration with MitraKeluargaHospital and TNI AL Marine Corps. The activities carried out including free post flooding treatment and the giving out of baby food.

Straight from the location, Dr Sujitno Fadli one of the medical team explained that there are about 545 patients that came for check ups. The community’s enthusiasm is very high. This could be seen during the time of registration that was suppose to be closed at 14.00 lasted much longer because there were so many people. The diseases mostly found were muscle pain, flu, skin diseases (eczema and daphnia) There were also people who still complain of having diarrhea as well as needing to have their wounds treated.

Besides the above activities, during this post-flooding time, Kalbe Farma also distributed medications such as Entrostop, Kalpanax, etc through 60 organizations and flood posts to areas that were flooded. “Besides distributing medications we also give out banner to remind people about the importance of cleanliness to keep diseases namely diarrhea and skin diseases at their minimum” explained Mr. Abdi Aydi Jaya of Kalbe Farma, as one of the event’s coordinators.

The activity is part of Kalbe Shares program which is a CSR project from PT Kalbe Farma Tbk that has been going on for a long time and being carried out continuously, covering aids in the field of education, health and facility repairs.
Kalbe hopes that these activities may contribute in building up the general community’s welfare.

Promag Received Indonesian Original Product Award 2006

The Indonesian Original Product 2006 Award held by the Indonesian Department of Trade and Harian Bisnis Indonesia, Indonesian business newspaper, Promag received the best Indonesian Original Product Award in the category of Over The Counter Medication.

Mari Elka Pangestu, the Indonesian Minister of Trade, attended the event.

The award is acknowledgement of Promag’s existence as a high quality local product with a powerful market competence and therefore becomes the first choice in the Indonesian community. The award also completes the range of other awards received by Promag namely ICSA (Indonesian Customer Satisfaction Award) 2000 -- 2006, IBBA (Indonesian Best Brand Award) 2004 -- 2006, as well as an award from IPRA (International Public Relation Association) - Indonesia 2006.

Kalbe Farma Grew By 1.41% in YTD September 2006

PT Kalbe Farma Tbk. (“Company”) today announced financial results for the quarter ended Sep 30, 2006.

Throughout the period of nine months of 2006, the Company sales performance has increased by 1.41% to Rp 4.49 trillion versus Rp 4.43 trillion last year.

Gross profit margin increased from 50.9% of Net Sales from last year to become 51% of Net Sales for the nine months period of 2006. This is due to the favorable and stable US Dollar exchange rate resulting in favorable cost of raw material that is mostly imported.

Operating expense increased by 5.27% compared to the same period last year. The Company will further make utmost efforts to minimize its expenses particularly its selling expenses so as to be in proportion with its sales growth towards the year end.

Operating Profit reached Rp 853 billion which is 4.11% lower than the previous year’s which was Rp 890 billion. Operating profit ratio decreased from 20.1% of Net Sales to become 19% of Net Sales this year.

However, the Company posted net profit of Rp 540 billion; 5.71% higher than 2005’s figure which was Rp 511 billion. The growth is mainly contributed by the increase in interest income, decrease in financial expenses and the reduction in foreign exchange loss.

CORD BLOOD STORAGE, Now Available in Indonesia

There is no need to go to Singapore to store your baby’s cord blood - which is rich in stem cells because Indonesia will have its own “Cord Blood Storage” put together by CordLife Singapore in collaboration with PT Kalbe Farma. Stem cells that may be used for therapies of cancer, heart diseases, diabetes up to bone damage is not only useful for the owner of the cord blood but also his close relatives.

The cost is considered economical. The fee for cord blood extraction is 8 Million IDR. Storage fee is 1.2 Million IDR per year. Compare the fees with storing the cord blood in Singapore which could reach up to S$ 5.000 to S$ 10.000.

The construction plan for Cord Blood Storage in Indonesia is warmly welcomed by the Health Minister, Siti Fadillah Supardi. In the press conference held by PT Kalbe Farma, in Jakarta, Saturday (14/10), the Health Minister said with the increasing number of patients suffering from degenerative diseases and blood disorders, stem cell transplantation technology is inevitable.

“The realm of health education is developing and Indonesia cannot always be left behind. All these while, mothers who had just given birth have let their babies’ cord blood be taken away. They only know about the old myths of taking the piece of umbilical cord at home,” she said.

Dr Sunny Tan Chiok Ling from CordLife Singapore explained; during pregnancy, the umbilical cord is the only life connection between the mother and the baby. If all these times, umbilical cords are discarded and buried, in 1963, the medical world found that stem cells from this cord blood and umbilical cord may be used by the bay as well as his family to cure various diseases.

“This is because the blood in the umbilical cord contains millions of stem cells which can initiate the formation of blood type similar with stem cells found in the bone marrow. The stem cells in the bone marrow and cord blood have been successfully harnessed to cure many life threatening blood disorders,” he said.

The first stem cell transplantation was done in France in 1988 for a Fanconi anemia sufferer. At present there are already more than 3.000 stem cell transplantations and more than 72 diseases cured by it. Most of them are acute illnesses such as leukemia, non-Hodgkin's Lymphoma, aplastic anemia, and autoimmune diseases.

In the future, researchers believe that stem cell may be used to repair body organs such as heart and pancreas (diabetes), and help to treat diseases namely systemic lupus erythematosus (SLE), multiple sclerosis, stroke, alzheimer, and parkinson.

The interest of Indonesia’s community to store their children’s umbilical cord in a cord blood storage seems to increase. According to Yuliana Indriati from the Kalbe Farma Stem Cells Development Division, at the moment there are about 100 people in Indonesia who stored umbilical cords in CordLife Singapore. One of them is from the baby of Maya Rumantir.

“I see the community’s enthusiasm in Indonesia to store cord blood is pretty big. Seen from the requests of some patients in a number of hospitals in Jakarta. But, because the stem cord storage facilities in Indonesia is still under development stage, the storage is done in Singapore. The cost is more expensive, which is 12 Million IDR for extraction,” said Indriati.

The request for cord blood extraction procedure is done by the patient during pregnancy. At the time of delivery, the cord blood is left in the placenta, which is clamped and cut. Using a safe technique, the doctor will put the cord blood into a blood bag.

The process is safe and painless for both the mother and the baby.

“The blood bag method is a more sterile process and storage compared to other methods. Stem cells will be stored in liquid nitrogen container at – 196 degree Celsius. It enables the cells to be preserved safely. Stem cells may be used in the future when needed,” she said.

Questioned about the storage time limit, Indri said, it is unlimited, it depends on the client’s wish. Even though the stem cell is not used on the related child, it may be used for his family. “When used on close relatives, the rejection factor is very small because it has similar genetic characteristics,” she said. (Tri Wahyuni)

Source in BAHASA: http://www.suarakarya-online.com/news.html?id=1582

Leading Indonesian pharma company, Kalbe Farma, invests in CyGenics subsidiary, CordLife Indonesia

Leading tissue and cord blood banking company CyGenics Ltd. (ASX: CYN) today announced Indonesia's leading pharma company, Kalbe Farma, has taken a 49% stake in its cord blood banking subsidiary, CordLife Indonesia.

This is a further, important step in CyGenics strategy of focusing on its core business of tissue and cord blood banking, and greatly strengthens its presence in a large and important market in the Asian region. The expansion of the Indonesian operations is in line with CyGenics' focus on revenue generating cord blood banking services and on establishing a sound presence in all major markets in the Asian region.

Kalbe Farma is the largest publicly-listed pharmaceutical company in Southeast Asia, with a market capitalisation of approximately US$1.5 billion and US$600 million in revenue in 2005. Kalbe Farma has over 12,000 employees, which includes a sales force of 6,000 covering 80% of the Indonesian consumer health market. Further, it is the dominant supplier to the Indonesian prescription pharmaceutical market.

CordLife Indonesia has been in operation since December 2003. The cord blood units have been couriered to Singapore, for processing and storage at the company's AABB-accredited facility. The volume of business in Indonesia has grown to the extent that the operations now require a processing and storage facility in the country. The investment by Kalbe Farma will enable CordLife Indonesia to proceed with these plans. The new facility is expected to be fully operational by early 2007, and the company intends to seek AABB accreditation for this facility.

Kalbe Farma will make a significant contribution towards growing the business through its vast hospital sales force of 6,000 people, and extensive hospital and birthing centre network. CordLife Indonesia will launch an expanded marketing and sales program for the cord blood banking business later this year.

"We have been looking for some time for a suitable partner towards building a business around tissue banking and cell therapy solutions in Indonesia", said Boenjamin Setiawan, President Commissioner, Kalbe Farma. "CordLife has been operating in Indonesia for some time, with a good team of people and a strong reputation. The CyGenics group has the best expertise in this region in terms of operational experience in many markets, quality standards, and so on. I believe together we will be able to do great things and lift CordLife Indonesia to the next level of growth."

"With its close proximity to Singapore and a projected five million births in 2006 alone, Indonesia has always been a key market for future expansion for our CordLife operations," said Steven Fang, Group CEO, CyGenics. "We are pleased to welcome Kalbe Farma as a valuable partner, and we look forward to being able to reaching a great many more people with our cord blood banking service."

Kalbe In-house Show & Pharma Forum 2006

Cheap Revolution influences all of daily life’s aspects. The pharmaceutical industry is no longer immune to this issue, as said by Johannes Setijono, the President Director of PT Kalbe Farma Tbk when opening Kalbe In-house Show & Pharma Forum 2006, Thursday 21 September 2006 at Cikarang, Bekasi Jawa Barat.



Cheap Revolution

According to Indonesia Innovator of the Year 2006 from CNBC Asia Pacific, Cheap Revolution is a massive event that occurred on account of globalization that overwhelms the world. Costumers are smarter in spending their money as well as increasing their demands for quality and comfort. As days passed the price for goods and services decline.

Some of the causes are: technology revolutions, real time media, the increase of productivity, price information from the internet, mass production, etc. Besides that, the pharmaceutical company in particular, is being demanded to reach a certain quality standard namely, cGMP, ISO 9001, ISO4001, OHSAS 18001 & Total Quality Management.

To achieve the above standards with high quality products and efficient cost, there is a way called Outsourcing.

Outsourcing system is commonly used by overseas companies – this benefits both parties. For the outsourcing contributor, this may decrease investments when there are new and high tech products in line. For the outsourcing recipients, the possessed capacity may be used to the maximum.

With outsourcing, the company may become tougher in facing cheap revolution. Slowly but surely, the products manufactured will become relatively cheaper, except the products that are still in patent period, said Johannes.

Can the "Local" manufactures survive without partnership?

The above question becomes the base of Santoso Oen’s explanation regarding the challenges in the world of pharmaceutical producer these days. As an example, the Director of PT Kalbe Farma Tbk quoted news regarding Vietnam’s pharmaceutical industry. Around 100 local pharmaceutical companies (out of 200) are at risk of being closed down. Some of the reasons are the increasing production costs and the demands from Vietnam’s National Agency of Drug and Food Control for higher quality. Such things may become an idea for the companies in Indonesia, both big and small to start thinking about production pattern that may depress the production and development costs, to hold back investment process cost and decrease quality management cost.


Besides taking up explanations from pharmaceutical outsourcing experts, participants can also look at the opened booths. Various booths that depicts the production process, quality control, supply chain management, packing, etc. were shown at Kalbe Farma office in Cikarang, Bekasi Jawa Barat.

Stem Cell Press Conference Symposium: New Hope in the Medical World

On 11 Augusts 2006, Medicastore participated in Stem Cell Press Conference Symposium which was held at the Anatomy Lecture Room FKUI by Fraunhofer Institute Germany working together with the University of Indonesia Medical Faculty and sponsored by PT Kalbe Farma, Tbk.

Speakers in attendance:
1. Prof. Dr. dr. M. Farid Aziz, SpOG (K), MRU FKUI Indonesia.
2. Dr. Johannes Bolze, Director and Principal Investigator Stroke Fraunhofer Institute German.
3. dr. Boenjamin Setiawan PhD, PT Kalbe Farma Tbk.
4. dr. Bambang Budi Siswanto, FIHA,. Vice Chairman of the Stem Cell Symposium Comittee

As moderators:
1. dr. Erik Tapan, MHA, Reflection of the Medical World
2. IBK Narayana Dr, Ing, Fraunhofer Representative Office Indonesia.

Hereon the detailed information:

Stem Cell = Miracle Cell
There are several diseases that are previously incurable by conventional therapies (chemotherapy and radiotherapy) such as multiple myeloma, chronic lymphatic leukemia, thalassemia major. Fortunately, now, there is a new hope.

In the last several years, there is a development in the medical world especially in the field of hematology and stem cell transplantation. “Stem Cell is the fifth phase in the medical history after the use of herbal and screening which continues to the discovery of cure for syphilis, the discovery of penicillin by Alexander Fleming and biotechnology,” said dr Boenyamin.

Stem Cell is a very unique cell because it has an amazing potential to develop and able to change into new cells or to become cells of other body organs. Stem cell has the assignment to repair abnormalities in the body and theoretically, stem cell may divide infinitely to fill other cells for the body as long as the person or animal still alive. When a Stem Cell divides or becomes other cell with more specific functions, such as muscle cell, red blood cell, brain cell, liver cell, kidney cell, etc.

The sources of Stem Cells are:
Stem cell from embryo (embryonal stem cells)Taken from an embryo in the blastoporic stage, the mass inside the cell grouped and contains embryonic stem cell. The cells are then isolated from the inside and cultured by in-vitro method. The stem cell will become specialized and then turn to be blood cells, muscle cells, liver cells and kidney cells.
Adult stem cells
One of them is hematopoietic stem cells. A stem cell that is able to create red blood cells, white blood cells and healthy blood platelets, usually found in bone marrows, periphery blood and umbilical cord blood.

“In America, a stem cell coming out from an embryo is banned by President Bush because it was considered as taking someone’s life. From 60 stem cells successfully created, in the US research unit, only 20 stem cell are still in function,” said dr. Boenyamin

Stem cells are found aplenty in the umbilical cords of newborn babies. That is why the blood from the umbilical cord can be stored and used when needed in the future. Even Korea, Thailand and Singapore have created facilities for umbilical cord blood storage. One of the banks for umbilical cord storage from newborn babies is Cordlife, Singapore. The storage costs S$2000 and there is an annual fee of S$200 for maintenance fee. “In Indonesia, the collecting of umbilical cords are available at RS Lippo Karawaci and RS Mitra Keluarga,” said Dr. Narayana.

Sources for stem cell transplant:
Family members or a donor with no family connection
Identical twins
Stem cell from the patient himself that has been stored beforehand

The Future in Indonesia
“In the medical world, especially medicine, Indonesia is above international standard,” said Dr. Narayana. Hence, initiated by PT. Kalbe Farma Tbk. Indonesia in collaboration with Fraunhofer Indonesia and several universities in Indonesia set up a group of stem cell research (ABG) with the support from the government through the Minister of Research and Technology.

Fraunhofer is a non-profit organization from Germany, which moves in the field of research and has 13.000 researchers made up of 500 professors and about 5.000-6.000 doctors. Fraunhofer’s main focus is to create a network between researchers and related institutes and henceforth found new businesses that supports research.“Fraunhofer has patented the stem cell culture and cell therapy, therefore it will act as a partner for the stem cell research in Indonesia,”verified Dr. Narayana.

ABG (Academicians, Business & Government) Is a stem cell research group made up of academicians, corporation and the government namely University of Indonesia, Bogor Institute of Agriculture, AtmajayaUniversity, PT Kalbe Farma Tbk. Lembaga Ilmu Pengetahuan Indonesia (LIPI) and Badan Penelitian dan Pengkajian Teknologi (BPPT). “The purpose of ABG is to create a focused coordination and collaboration in doing stem cell research in Indonesia, therefore it does not have to be done separately and the result could be use more effectively,” said dr.Boenyamin

The Universities are made up of educators and researchers with the hope that the research result may be enjoyed by the whole community. “The research costs may be supported by the Industry where the research may not only be used as a commodity but also reach the community,” explained Prof.Dr. Farid. Korea, UK, America and Germany pioneered the world’s stem cell research.

These three elements (academicians, business and government) will be thrown together to wipe out the stereotypes that have been formed in the community. The business stereotype is that they only look for profits, the academician stereotype is they only good for theory, but slow in practice and the government’s stereotype is that they complicate research with complex bureaucracy and very limited budget. In this case, the government is expected to be the catalyst of stem cell research in Indonesia and the Industry sector is hoped to be able to fund and even give incentive and therefore the whole Indonesian community may use the result. As comparison, other Asian countries have given high incentives for doctors who are doing stem cell research.

New Hope in the Medical World
In the human body, stem cell is usually concealed in the areas of bone marrow that are lack in oxygen. It is usually unveiled when the body suffers from an injury, and goes towards the injured areas. For example, it goes into the brain cell when the victim had a stroke, leukemia and so on. But stem cell can not help when stroke, leukemia or other diseases have become acute.

Stem cell is the new hope to cure diseases that are hard to treat. Stem cell therapy is also called cellular transplant. Stem cell may be specialized to become brain cells, heart cells, backbone marrow and other cells in the body. “First, the stem cell is cultured, for example, to be a heart cell and then the heart cell is harnessed and afterwards put into the heart through a catheter,” clarified dr.Bambang.

Stem cell has been proved to treat multiple myeloma chronic lymphatic leukemia, thalassemia major, heart miokard infarct, stroke, alzheimer, etc. Stem cell research team in Indonesia has targeted that Indonesia is able to create stem cell for stroke in the next 3-5 years. At the moment, the animal model has been developed.

Stem Cell Symposium

For more information regarding stem cell, and how to harness its potential in medical world, make sure to attend the stem cell symposium:

University of Indonesia Medical Faculty (Society Research and Dedication Manager) working together with PT. Kalbe Farma Tbk. and Journal Cermin Dunia Kedokteran (CDK) will organize a day symposium with the theme: Menyongsong Era Stem Cell di Indonesia (Greeting the Stem Cell Era in Indonesia) on Saturday, 2 September 2006 at the FKUI Hall

Registration at:

Redaksi majalah CDK (attn Dodi)

Gedung Enseval

Jl. Letjen Seprapto Kav.4

Telp:012-4208171, Fax: 012-42873685

Source in BAHASA http://www.medicastore.com

Now (2007), Indonesia has a Stem Cell and Cancer Institute
Address: Jl. Jend Ahmad Yani no. 2, Pulo Mas, Jakarta 13210 - Indonesia
Tel: +62 - 21 - 47860173